References
- Ahn D, Heo SJ, Park JH, et al (2011). Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer. Acta Oncol, 50, 1228-34. https://doi.org/10.3109/0284186X.2011.602109
- Briese J, Cheng S, Ezzat S, et al (2010). Osteopontin (OPN) expression in thyroid carcinoma. Anticancer Res, 30, 1681-8.
- Dailey, M.E., Lindsay, S. Skahen, R (1955). Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. A.M.A. Arch Surg, 70, 291-7. https://doi.org/10.1001/archsurg.1955.01270080137023
- Fedarko NS, Jain A, Karadag A, et al (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res, 7, 4060-6.
- Fiore E, Rago T, Latrofa F, et al (2011). Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer, 18, 429-37. https://doi.org/10.1530/ERC-11-0028
- Giachelli CM, Steitz S (2000). Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol, 19, 615-22. https://doi.org/10.1016/S0945-053X(00)00108-6
- Guarino V, Faviana P, Salvatore G, et al (2005). Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab, 90, 5270-8. https://doi.org/10.1210/jc.2005-0271
- Hollowell JG, Staehling NW, Flanders WD et al (2002). SerumTSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metabolism, 87, 489-99. https://doi.org/10.1210/jcem.87.2.8182
- Huang BY, Hseuh C, Chao TC, et al (2011). Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence. Endocr Pathol, 22, 144-9. https://doi.org/10.1007/s12022-011-9164-9
- Hundahl SA, Fleming ID, Fremgen AM et al (1998). A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 83, 2638-48. https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
- Kashima K, Yokoyama S, Noguchi S, et al (1998). Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid, 8, 197-202. https://doi.org/10.1089/thy.1998.8.197
- Kim EY, Kim WG, Kim WB, et al (2009). Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf), 71, 581-6. https://doi.org/10.1111/j.1365-2265.2009.03537.x
- Kim KW, Park YJ, Kim EH, et al (2011). Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. Head Neck, 33, 691-5. https://doi.org/10.1002/hed.21518
- Kim SS, Lee BJ, Lee JC, et al (2011). Coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma: the influence of lymph node metastasis. Head Neck, 33, 1272-7. https://doi.org/10.1002/hed.21594
- Kwak JY, Kim EK, Kim JK, et al (2010). Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation prevalent area. Head Neck, 32, 490-8.
- Kyung Ho Kang (2013). Osteopontin expression in papillary thyroid carcinoma and its relationship with the BRAF mutation and tumor characteristics. J Korean Surg Soc, 84, 9-17. https://doi.org/10.4174/jkss.2013.84.1.9
- Liu W, Li Z, Luo Q, et al (2011). The elevated expression of osteopontin and vascular endothelial growth factor in sinonasal inverted papilloma and its relationship with clinical severity. Am J Rhinol Allergy, 25, 313-7. https://doi.org/10.2500/ajra.2011.25.3662
- Loh KC, Greenspan FS, Dong F, et al (1999). Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab, 84, 458-63. https://doi.org/10.1210/jcem.84.2.5443
- Oates AJ, Barraclough R, Rudland PS (1996). The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene, 13, 97-104.
- Rittling SR, Chambers AF (2004). Role of osteopontin in tumour progression. Br J Cancer, 90, 1877-81. https://doi.org/10.1038/sj.bjc.6601839
- Singh B, Shaha AR, Trivedi H, et al (1999). Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery, 126, 1070-6. https://doi.org/10.1067/msy.2099.101431
- Wang KX, Denhardt DT (2008). Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev, 19, 333-45. https://doi.org/10.1016/j.cytogfr.2008.08.001